Tyco sees global prospects in $3.1 billion Bard deal
This article was originally published in Clinica
Executive Summary
Tyco International, owner of significant brand names in the device industry such as US Surgical and Mallinckrodt, is to become the largest company in the market following its agreed bid to purchase CR Bard for $3.1 billion in shares. Bard made sales of $1.1 billion in 2000, with Tyco turning over some $6.5 billion from healthcare activities to September 2000. It closed the acquisition of $2.5 billion turnover company Mallinckrodt after the end of the financial year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.